$1 million grant supports trial of experimental treatment for ALS
August 24, 2026
MP-101 designed to improve mitochondrial function, support energy production.
The ALS Association has awarded Mitochon Pharmaceuticals a $1 million grant to support a Phase 2 clinical trial testing the company’s experimental therapy MP-101 in people with amyotrophic lateral sclerosis (ALS).
The study is still in the planning stages and is expected to kick off next year.
“We are honored to receive such a significant award,” Robert Alonso, CEO of Mitochon, said in a company press release. “It is a great endorsement of the idea of using a mitochondrial uncoupler as a treatment for ALS and will help fund the Phase II study planned for early 2027.”
About Mitochon Pharmaceuticals
Mitochon was founded in 2014 with the mission to develop treatments for insidious diseases through the modulation of mitochondrial physiology, with applications to neurodegeneration, neuromuscular, and developmental diseases. Mitochon’s lead programs, MP101 and MP201, specifically harnesses the power of the mitochondria to provide broad neural protection. These compounds elicit mild increases in energy expenditure that result in strengthening cellular survival—similar to the positive effects seen with fasting and exercise. These compounds also induce an important neurotrophin, Brain Derived Neurotrophic Factor (BDNF), involved in cognition and neural growth. Mitochon is supported by Ben Franklin Technology Partners Southeastern PA, an initiative of the Pennsylvania Department of Community and Economic Development funded by the Ben Franklin Technology Development Authority.